First stem cell-based veterinary medicine recommended for marketing authorisation

Tuesday 26 Jun 2018 @ 09:25
EU News

Arti-Cell Forte is indicated in horses with mild to moderate lameness due to joint inflammation.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Veterinary Use (CVMP) has recommended a marketing authorisation for the first veterinary stem cell-based medicine in the European Union (EU). These types of medicines have the potential to provide new treatment strategies.

Arti-Cell Forte is a veterinary medicine indicated for the reduction of mild to moderate lameness linked to joint inflammation in horses. The medicine is available as a suspension for injection and is given as a single injection into the affected joint. It contains a type of stem cell obtained from equine blood. Stem cells are cells that can develop into different types of cells. The stem cells in the medicine are treated so that they develop towards cartilage cells which can assist in repairing damaged cartilage in the joint. Arti-Cell Forte expands the range of available treatments for lameness in horses.

In a field study conducted in horses with lameness of the fetlock joint, Arti-Cell Forte showed a statistically significant improvement in the horses treated with the medicine compared with a placebo control group six weeks after treatment. The positive effect of treatment was sustained over one year. In this study a single systemic administration of a nonsteroidal anti-inflammatory drug (NSAID) was given concurrently to treatment with Arti-Cell Forte.

The most common side effects were mild increase in lameness and injection site reactions in the first week after treatment.

The applicant for Arti-Cell Forte sought scientific advice from the Agency during the development of the medicine. Scientific advice is EMA’s key tool to encourage and support the development of new and innovative medicines. The CVMP opinion will now be sent to the European Commission for a decision on an EU-wide marketing authorisation.

Notes:

The applicant for this veterinary medicinal product is Global Stem cell Technology NV.

Related information

Arti-Cell Forte: Pending EC decision

Related content

Contact point:

EMA press office
Tel. +44 (0)20 3660 8427
Email: press@ema.europa.eu
Follow us on Twitter @EMA_News

Original article link: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/06/news_detail_002978.jsp&mid=WC0b01ac058004d5c1

Share this article

Latest News from
EU News

EU increases humanitarian aid to Gaza by €25 million

07/11/2023 13:25:00

As part of the EU's continued support to people in Gaza, the Commission will provide a further €25 million in humanitarian aid. This quadruples EU humanitarian assistance to over €100 million for Gaza this year.

President von der Leyen marks the EU's commitment to the Partnership for Global Infrastructure and Investment (PGII) during the event hosted at the G20 in New Delhi

12/09/2023 15:25:00

President von der Leyen recently (09 September 2023) spoke at the G20 event on PGII hosted by Prime Minister Modi and President Biden.

Summer 2023 Economic Forecast: Easing growth momentum amid declining inflation and robust labour market

12/09/2023 13:25:00

The European Commission yesterday presented the Summer 2023 Economic Forecast

Climate change: Deal on a more ambitious Emissions Trading System (ETS)

20/12/2022 10:33:00

On Saturday night, MEPs and EU governments agreed to reform the Emissions Trading System to further reduce industrial emissions and invest more in climate friendly technologies.

EU and Ukraine sign €100 million for the rehabilitation of war-damaged schools *

20/12/2022 09:25:00

Exactly three months after President von der Leyen's announcement in her 2022 State of the Union Address, the European Commission and the Government of Ukraine have signed a €100 million support package for the reconstruction and rehabilitation of schooling facilities damaged in Russia's full-scale war of aggression against Ukraine.

NextGenerationEU: European Commission endorses positive preliminary assessment of Portugal's second request for €1.8 billion disbursement under the Recovery and Resilience Facility

19/12/2022 16:33:00

The European Commission recently (16 December 2022) endorsed a positive preliminary assessment of Portugal's payment request for €1.8 billion of grants and loans under the Recovery and Resilience Facility (RRF), the key instrument at the heart of NextGenerationEU.

WIREDGOV